did the speaker's paper show hallucinogen er visits rise as use rises?
“We published a paper looking at the number of uh ED visits and hospitalizations as a result of hallucinogens. And what we have shown is that as use goes up, the number of ED related harms”
a guest, director of a dual diagnosis addiction clinic at Stanford (psychiatrist) said on Huberman Lab, 2026-11-09, at 1:05:49. hear it in context → the speaker cited: a paper her group published.
first, the part that holds
the paper is real and says what the speaker says it says about visits: a stanford psychiatry group published it in addiction in 2024, and it found hallucinogen-associated emergency department visits in california rose 54% from 2016 to 2022 (2,260 to 3,476), with hospitalizations up about 55%. hallucinogen use did rise nationally over the same years, according to federal survey data.
what we found when we went and looked
we read the paper's abstract on pubmed. it is an ecological study of california hospital diagnosis codes. it counted hallucinogen-associated emergency visits (up 54%, 2,260 to 3,476) and hospitalizations (up about 55%) from 2016 to 2022. it did not measure hallucinogen use, so it cannot show harms rising "as use goes up". that link comes from putting the paper next to separate national survey data, where past-year hallucinogen use among 19–30-year-olds went from 5% in 2017 to 8% in 2022. a 2025 national study of insurance claims by a different group found hallucinogen-related admission rates rising until april 2020 and then falling through 2023, while survey-reported use kept going up. so harms and use do not simply move together.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| the speaker's group published a paper on hallucinogen-related emergency department visits and hospitalizations | confirmed | trends in hallucinogen-associated emergency department visits and hospitalizations in california, usa, from 2016 to 2022, addiction 2024;119(5):960-964. three of its four authors are listed in stanford's department of psychiatry and behavioral sciences. [1] |
| hallucinogen-related emergency department visits and hospitalizations rose | confirmed | ed visits rose 54% (2,260 to 3,476) and hospitalizations rose about 55% in california between 2016 and 2022. over the same years alcohol-associated ed visits fell 20% and cannabis-associated ed visits rose 15%. the data cover one state and come from diagnosis codes. [1] |
| the paper found these harms rise as hallucinogen use rises | misattributed | the paper is an ecological count of icd-10 diagnosis codes from california's department of healthcare access and information. its abstract reports no measure of hallucinogen use and no rate per user. 'as use goes up' is an inference from separate survey data, not something the paper found. the 2025 national claims study found admission rates fell from april 2020 to march 2023, a period when survey-reported use was rising. [1][2][3] |
| hallucinogen use has been rising in the us | confirmed | in monitoring the future panel data, past-year hallucinogen use (lsd, mdma, mescaline, peyote, psilocybin, pcp) among 19–30-year-olds was 3% in 2012, 5% in 2017 and 8% in 2022. among 35–50-year-olds it was 1% or less in 2017 and 4% in 2022. these are national figures, not california ones. [3] |
| the increase is large in absolute terms | overstated | the paper's own conclusion calls it 'a large relative but small absolute increase'. hallucinogen visits stayed in the low thousands per year, while alcohol- and cannabis-associated visits ran into the hundreds of thousands. the speaker did not make this claim; we include it because the numbers are often repeated without it. [1] |
both directions
for the speaker: the paper exists, it comes from the speaker's department, and its numbers match the description: hallucinogen-associated ed visits up 54% and hospitalizations up about 55% from 2016 to 2022. alcohol-associated ed visits fell 20% and cannabis-associated visits rose 15% over the same years. federal survey data show past-year hallucinogen use among young adults rising from 5% in 2017 to 8% in 2022, so over the paper's study window, use and visits did rise together.
against: the paper never measured use. it counts encounters, not encounters per person who uses, so it cannot say whether harm per use went up, went down or stayed flat. if use grew faster than 55% over those years, the risk per user could even have fallen. a separate 2025 national study of commercial and medicaid claims found hallucinogen-related admission rates rose 0.62% per month until april 2020 and then fell 0.76% per month through march 2023, while survey-reported use stayed at record highs. its authors write that admissions 'remain relatively rare' and that the trends are hard to pin on specific causes. the paper's own conclusion stresses that the absolute increase was small.
what this cannot say
we read the pubmed abstract of the addiction paper; the publisher's full text was blocked (403), so a use-related analysis that appears only in the full text would not have shown up here. icd-10 codes for 'hallucinogen' disorders are coarse and depend on how clinicians code. the category may include drugs listed in the paper's keywords, such as mdma and ketamine, alongside classic psychedelics, and coding habits can change over time. the use data are national panel surveys, not california figures, so we cannot line up use and visits within the same state. the 2025 national study covers only insured people aged 16–64, and we could not confirm from what we read what its rate denominator was.
sources, each one fetched and read
- stanford university department of psychiatry and behavioral sciences et al., trends in hallucinogen-associated emergency department visits and hospitalizations in california, usa, from 2016 to 2022, addiction 2024;119(5):960-964, doi:10.1111/add.16432, pmid 38213013 What we read there: 'We conducted an ecological study with publicly available data on ICD-10 diagnosis codes associated with emergency department (ED) visits and hospitalizations' from california hcai; 'Observed hallucinogen-associated ED visits increased by 54% between 2016 and 2022, from 2260 visits to 3476 visits, compared with a 20% decrease in alcohol-associated ED visits and a 15% increase in cannabis-associated ED visits'; conclusion: 'a large relative but small absolute increase'. Fetched 2026-11-10 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/38213013/
- washington university school of medicine et al., trends in hallucinogen-related emergency department and hospital admissions, 2016 to 2023, jama network open 2025, doi:10.1001/jamanetworkopen.2025.43453 What we read there: of 1,355,161 people with substance-related admissions, 21,700 (1.6%) had a hallucinogen-related admission; 'From January 2016 to April 2020, monthly rates increased by 0.62% ... per month. From April 2020 to March 2023, rates declined by 0.76%'; 'self-reported hallucinogen use is rising in the United States; however, emergency and hospital admissions involving hallucinogens remain relatively rare.' Fetched 2026-11-10 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC12616458/
- national institute on drug abuse, news release on monitoring the future panel study results, august 17, 2023 What we read there: past-year hallucinogen use among adults 19–30 was 8% in 2022, 5% in 2017 and 3% in 2012; among adults 35–50 it was 4% in 2022 and 1% or less in 2017; hallucinogens counted: lsd, mdma, mescaline, peyote, psilocybin and pcp. Fetched 2026-11-10 (HTTP 200). https://nida.nih.gov/news-events/news-releases/2023/08/marijuana-and-hallucinogen-use-binge-drinking-reached-historic-highs-among-adults-35-to-50
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam